To ask the Secretary of State for Health and Social Care, pursuant to the oral contribution of the Minister of State for Health and Social Care on 17 June 2025, Official Report col 352, what his planned timescale is for a decision of the NHS England Clinical Priorities Advisory Group in relation to commissioning of abiraterone acetate plus prednisone for hormone-sensitive non-metastatic prostate cancer, following the sharing of updated cost impact modelling from Prostate Cancer UK.
In regard to funding for abiraterone specifically, abiraterone is not licensed for use in the treatment of high-risk, non-metastatic hormone-sensitive prostate cancer, and as such cannot be evaluated by the National Institute for Health and Care Excellenc...
Prostate Cancer: Medical Treatments